About
Guardant Health is a precision oncology company headquartered in Palo Alto, CA, dedicated to transforming cancer care through the power of blood-based diagnostics and data science. Their flagship products include the Shield™ Blood Test for colorectal cancer screening, Guardant Complete® for comprehensive tumor profiling, and InfinityAI powered Guardant Infinity™ for advanced multi-omic analysis. By analyzing circulating tumor DNA (ctDNA) found in a simple blood draw, Guardant Health's tests provide oncologists with actionable genomic insights to guide personalized treatment decisions — without the need for invasive tissue biopsies. The platform supports the full cancer care continuum: early detection and screening, minimal residual disease (MRD) monitoring, therapy selection in advanced-stage cancer, and assessment of treatment response. With over 500,000 tests performed across 12,000 clinicians, Guardant Health also partners with biopharmaceutical companies to accelerate drug development through its BioPharma Solutions division. Their InfinityAI platform applies artificial intelligence to multi-omic data for deeper tumor characterization. Guardant Health serves patients, oncologists, institutional healthcare partners, and biopharma researchers seeking data-driven, minimally invasive oncology solutions.
Key Features
- Shield™ Blood Test for Colorectal Cancer Screening: A non-invasive blood test that screens for colorectal cancer, now accessible through Quest Diagnostics' national collection network.
- Guardant Complete® Tumor Profiling: Comprehensive liquid biopsy test that analyzes ctDNA to identify actionable genomic alterations and guide therapy selection for advanced cancer patients.
- InfinityAI & Guardant Infinity™: AI-powered multi-omic liquid biopsy platform for deeper tumor characterization, combining genomic, epigenomic, and proteomic signals.
- Minimal Residual Disease (MRD) Monitoring: Detects residual cancer cells after treatment using circulating tumor DNA, enabling early intervention before clinical relapse.
- BioPharma Solutions: Partners with pharmaceutical and biotech companies to integrate liquid biopsy data into clinical trials and drug development programs.
Use Cases
- Oncologists ordering comprehensive tumor profiling via liquid biopsy to select the most effective targeted therapy for advanced cancer patients.
- Primary care physicians and gastroenterologists using the Shield™ Blood Test to screen average-risk patients for colorectal cancer without colonoscopy.
- Cancer patients undergoing treatment using Guardant's MRD monitoring tests to detect residual disease and assess whether therapy is working.
- Biopharmaceutical companies partnering with Guardant Health to enrich clinical trial cohorts and develop companion diagnostics using liquid biopsy data.
- Institutional oncology centers integrating Guardant Health's multi-omic InfinityAI platform to improve tumor classification and personalize treatment protocols.
Pros
- Non-Invasive Testing: Blood-based liquid biopsies eliminate the need for painful surgical tissue biopsies while still delivering comprehensive genomic insights.
- Clinically Validated at Scale: Over 500,000 tests performed by 12,000+ physicians, backed by extensive clinical studies and peer-reviewed publications.
- Full Cancer Care Continuum Coverage: Products address every stage from early screening to advanced-stage therapy selection and post-treatment monitoring.
- AI-Driven Multi-Omic Analysis: InfinityAI applies artificial intelligence to multi-omic data, enabling more precise tumor typing and treatment matching.
Cons
- High Cost & Insurance Coverage Variability: Liquid biopsy tests can be expensive and insurance reimbursement is not always guaranteed, creating access barriers for some patients.
- Not a Standalone Diagnostic Tool: Results must be interpreted by qualified oncologists; the tests are decision-support tools, not definitive standalone diagnoses.
- Limited to Oncology Use Cases: The platform is highly specialized for cancer diagnostics and is not applicable to other medical or non-medical domains.
Frequently Asked Questions
What is the Shield™ Blood Test?
The Shield™ Blood Test is a non-invasive blood-based screening test for colorectal cancer. It detects cancer-associated DNA in the bloodstream and is available through Quest Diagnostics' national ordering and collection network.
How does Guardant Health's liquid biopsy technology work?
Guardant Health's tests analyze circulating tumor DNA (ctDNA) shed by cancer cells into the bloodstream. A simple blood draw is processed to identify genomic alterations, epigenetic signals, and other biomarkers that reveal the presence, type, and characteristics of cancer.
Who can order Guardant Health tests?
Guardant Health tests are ordered by licensed oncologists and physicians. Patients should ask their doctor whether a Guardant Health liquid biopsy is appropriate for their care.
What is InfinityAI and how does it differ from other Guardant tests?
InfinityAI is Guardant Health's AI-powered multi-omic analysis platform that powers the Guardant Infinity™ test. Unlike standard genomic panels, it combines multiple biological data layers — genomic, epigenomic, and more — using artificial intelligence to provide deeper tumor characterization and more precise tumor typing.
Does Guardant Health work with pharmaceutical companies?
Yes. Through its BioPharma Solutions division, Guardant Health partners with pharmaceutical and biotech companies to integrate liquid biopsy testing into clinical trials, companion diagnostic development, and drug development programs.
